Efficacy response in CF patients treated with ivacaftor: post-hoc analysis

Area of Science:

• Pulmonary Medicine
• Genetics
• Pharmacology

Background:

• Ivacaftor demonstrated improved clinical outcomes in cystic fibrosis (CF) patients with the G551D-CFTR mutation.
• Understanding ivacaftor's effect across diverse FEV(1) responses is crucial for optimizing treatment.

Purpose of the Study:

• To re-examine Phase 3 STRIVE/ENVISION trial data to assess ivacaftor's efficacy across FEV(1) response distributions.
• To evaluate clinical outcomes including FEV(1), sweat chloride, weight, CFQ-R scores, and pulmonary exacerbations.
• To calculate the Number Needed to Treat (NNT) for specific clinical benefit thresholds.

Main Methods:

• Post-hoc analysis of 209 patients receiving 48 weeks of ivacaftor or placebo.
• Patients stratified into tertiles based on FEV(1) response.
• Comparison of outcomes between ivacaftor and placebo groups within each tertile.

Main Results:

• Ivacaftor treatment led to numerical improvements in FEV(1), sweat chloride, CFQ-R, and reduced pulmonary exacerbations across all tertiles.
• Statistically significant improvements were observed for all outcomes in the upper FEV(1) tertile and for some outcomes in the lower and middle tertiles.
• NNT values were 1.90 for a ≥5% FEV(1) improvement, 5.74 for a ≥5% weight increase, and 3.85 for preventing pulmonary exacerbations.

Conclusions:

• Ivacaftor therapy provides clinical benefits for cystic fibrosis patients with G551D-CFTR mutations, irrespective of their initial FEV(1) response level.
• The majority of patients with characteristics similar to those in the STRIVE/ENVISION studies are likely to benefit from ivacaftor treatment.
• This analysis supports the broad utility of ivacaftor in managing G551D-CFTR cystic fibrosis.